Remain invested in Aurobindo Pharma, says Avinnash Gorakssakar

Avinnash Gorakssakar, Market Expert told CNBC-TV18, "One should continue to hold on to Aurobindo Pharma. One has already got a very decent upside over the last six years. However, if one were to look at the financials for FY18, not only do valuations look pretty attractive, but even the earnings growth as well as the kind of regulatory impact for Aurobindo Pharma looks a lot better than the other pharmaceutical companies."

"I would believe that one could look at a price of around Rs 900 plus probably to book out some of the profits and the rest one can hold on," he added.